 Q BioMed Inc said its MAN-19 therapeutic, which it is developing with partner Mannin Research, is poised to start clinical trials in 2022. The MAN-19 therapeutic is a recombinant fusion protein and is being assessed to treat acute respiratory distress syndrome ARDS, which is caused by viral infections in the lungs including coronavirus COVID-19. 